# Breast Cancer

Breast cancer management requires subtype-, stage-, and patient-specific integration of surgery, systemic therapy, radiation, germline testing, and survivorship care. This review prioritizes decisions that alter treatment sequencing, adjuvant endocrine duration, recurrence surveillance, and management of male breast cancer.

**Clinical question:** How should clinicians individualize breast cancer treatment, surveillance, and survivorship care by stage, biologic subtype, and sex?

Updated: 2026-08-20T23:45:50.213934Z

## What matters in practice
- Use tumor histology, grade, clinical stage, ER, PR, and HER2 status to determine whether neoadjuvant systemic therapy is appropriate and whether residual disease will alter adjuvant treatment. [18]
- For high-risk HER2-positive or triple-negative disease, neoadjuvant systemic therapy can create an actionable post-treatment risk assessment based on residual disease. [18]
- Routine laboratory testing and nonbreast imaging are not supported for asymptomatic survivors being evaluated solely for recurrence; surveillance centers on history, examination, and breast imaging. [12]
- In hormone receptor-positive disease, endocrine therapy is foundational; duration beyond 5 years should reflect recurrence risk, treatment tolerance, and the diminishing incremental benefit reported beyond 7 to 8 years in some guidelines. [2]
- Men with hormone receptor-positive breast cancer should generally receive tamoxifen for an initial 5 years; aromatase inhibitor therapy, when used, should be combined with gonadotropin-releasing hormone suppression. [10]

## Start with anatomy, biology, and treatment intent

Treatment selection depends on whether therapy is curative-intent or disease-control–directed.

Initial management requires integration of clinical stage, tumor histology and grade, ER/PR and HER2 status, and patient factors. These variables determine operability, the role and timing of systemic therapy, radiation planning, and whether neoadjuvant treatment can guide adjuvant escalation. [14][18]

For early breast cancer, treatment sequencing should be deliberate rather than reflexive. ASCO recommends using histology, grade, stage, and ER, PR, and HER2 expression to decide on neoadjuvant chemotherapy. Neoadjuvant systemic therapy is particularly useful in high-risk HER2-positive or triple-negative disease when residual disease would change postoperative systemic treatment. [18]
- Use neoadjuvant therapy when it can change the operative approach or provide a response-adapted adjuvant treatment decision. [18]
- Avoid assuming that all hormone receptor-positive, HER2-negative tumors need preoperative chemotherapy; ASCO limits this approach to patients in whom the chemotherapy decision can be made without genomic assay or surgical-pathology information. [18]

*Clinical variables that should drive initial treatment sequencing. [14][18]*

| Clinical variable | Decision consequence |
| --- | --- |
| ER, PR, and HER2 status | Defines biologic subgroup and systemic treatment strategy; should inform neoadjuvant treatment decisions. [18] |
| Clinical stage and nodal status | Determines local-regional treatment needs and identifies patients in whom neoadjuvant therapy may be useful. [14][18] |
| Residual disease after neoadjuvant treatment | Can identify patients with HER2-positive or triple-negative disease for altered postoperative systemic therapy. [18] |
| Need for genomic or surgical-pathology information | Supports deferring chemotherapy decisions in many HR-positive, HER2-negative tumors until this information is available. [18] |

## Use neoadjuvant therapy when response will change the next treatment

The main value is not tumor downsizing alone; it is response-adapted treatment selection.

For high-risk HER2-positive or triple-negative breast cancer, neoadjuvant systemic therapy is recommended when residual disease would guide postoperative treatment. In this setting, failure to achieve pathologic complete response identifies a group with worse prognosis and an opportunity for adjuvant treatment modification. [18]

For clinically node-positive and/or at least T1c triple-negative breast cancer, ASCO recommends an anthracycline- and taxane-containing neoadjuvant regimen. Neoadjuvant therapy should not be routinely offered outside a clinical trial for cT1a or cT1bN0 triple-negative tumors. [18]

In postmenopausal patients with hormone receptor-positive, HER2-negative disease, neoadjuvant endocrine therapy with an aromatase inhibitor is an endorsed option. In contrast, preoperative chemotherapy in this subgroup should be reserved for cases in which the chemotherapy decision does not require tumor-specific genomic testing or final surgical pathology. [18]
- Document pretreatment receptor status and clinical burden before neoadjuvant treatment because both establish systemic-treatment intent and permit post-treatment risk interpretation. [18]
- Plan postoperative treatment before starting neoadjuvant therapy: residual HER2-positive disease may prompt trastuzumab emtansine, and residual triple-negative disease may support adjuvant capecitabine according to the evidence summarized by ASCO. [18]

*Neoadjuvant treatment selection principles. [18]*

| Clinical setting | Decision-oriented approach |
| --- | --- |
| High-risk HER2-positive disease | Offer neoadjuvant systemic therapy when residual disease would guide adjuvant treatment. [18] |
| High-risk triple-negative disease | Offer neoadjuvant systemic therapy when residual disease would guide adjuvant treatment; use an anthracycline- and taxane-containing regimen for clinically node-positive and/or at least T1c disease. [18] |
| cT1a or cT1bN0 triple-negative disease | Do not routinely offer neoadjuvant therapy outside a clinical trial. [18] |
| Postmenopausal HR-positive, HER2-negative disease | Neoadjuvant aromatase inhibitor therapy is an option; use neoadjuvant chemotherapy only when treatment selection does not depend on genomic testing or surgical pathology. [18] |

## Individualize endocrine therapy duration after five years

Late recurrence risk makes adherence and duration clinically consequential in hormone receptor-positive disease.

Guidelines consistently support at least 5 years of adjuvant endocrine therapy in hormone receptor-positive early breast cancer. The principal strategies described across guidelines are tamoxifen for premenopausal patients and aromatase inhibitor therapy, either initially or sequentially after tamoxifen, for postmenopausal patients. [2]

Extension should be individualized. Some guidelines support tamoxifen for up to 10 years in premenopausal patients or those unable to tolerate aromatase inhibitors, and extension of aromatase inhibitor therapy up to a maximum of 10 years in high-risk postmenopausal patients. [2] However, other guidelines note limited incremental benefit beyond 7 to 8 years, underscoring the need to weigh nodal status, tumor size and grade, tolerability, competing risk, and patient preference. [2]

This decision is particularly relevant because hormone receptor-positive tumors may recur decades after diagnosis, whereas hormone receptor-negative tumors have a very low recurrence rate beyond 8 years. [2]
- At each follow-up visit, assess adherence, adverse effects, and whether the original recurrence-risk rationale still supports continued treatment. [12]
- Avoid a uniform 10-year prescription: extended treatment is a risk-benefit decision, not a survivorship default. [2]

*Endocrine therapy decisions supported in long-term survivorship guidance. [2]*

| Patient context | Supported approach |
| --- | --- |
| Premenopausal HR-positive disease | Tamoxifen is recommended for at least 5 years; some guidelines support continuation up to 10 years based on risk and tolerance. [2] |
| Postmenopausal HR-positive disease | Aromatase inhibitor therapy may be initial or sequential after tamoxifen for at least 5 years. [2] |
| High-risk postmenopausal disease after initial endocrine therapy | Consider aromatase inhibitor extension, with total endocrine duration up to 10 years in selected patients. [2] |
| Potential treatment beyond 7 to 8 years | Discuss uncertain or limited incremental benefit reported by some guidelines. [2] |

## Surveil for recurrence without routine metastatic testing in asymptomatic survivors

Follow-up should detect actionable local events while avoiding low-value testing.

The American Cancer Society/ASCO survivorship guideline recommends regular cancer-related history and physical examination and screening for a new primary breast cancer. It does not support routine laboratory tests or imaging studies to search for recurrence in asymptomatic survivors. [12]

Long-term guideline synthesis identifies annual clinical follow-up beginning in the sixth year after primary treatment as a common recommendation. Annual mammography beginning in the fifth year is also broadly recommended, with individualization by age, relapse risk, tumor characteristics, and whether breast-conserving surgery or mastectomy was performed. [2]

Order laboratory tests or imaging other than breast-directed imaging when symptoms, examination, or other findings raise clinical suspicion for recurrence or metastasis, rather than as scheduled surveillance in asymptomatic patients. [2][12]
- Ask specifically about new breast or chest-wall findings, bone pain, chest pain, dyspnea, abdominal pain, and persistent headache; these symptoms warrant diagnostic evaluation rather than reassurance based on prior routine surveillance. [10]
- Maintain surveillance of endocrine therapy adherence and treatment-related symptoms that compromise quality of life. [12]
- A survivorship plan should communicate prior surgery, radiation, systemic therapy, ongoing endocrine treatment, anticipated late effects, and responsibility for surveillance between oncology and primary care. [2][12]

### Address late effects at each follow-up encounter

Long-term survivors report fatigue, chronic pain, lymphedema, sleep disturbance, anxiety, depression, and social or occupational consequences. Yet long-term survivorship guidelines incompletely address lymphedema, osteoporosis, cognitive effects, neuropathy, fatigue, sexual health, and other persistent toxicities. Clinicians should therefore actively elicit these concerns rather than infer their absence from disease-free status. [2]
- Assess psychosocial needs, work and family function, and sexual concerns as part of survivorship follow-up. [2]
- For survivors at elevated cardiovascular risk, one guideline recommends evaluation every 3 to 5 years, with more frequent monitoring after high cumulative anthracycline exposure or in older patients. [2]

*Survivorship surveillance actions and limits. [2][12]*

| Clinical context | Recommended action |
| --- | --- |
| Asymptomatic survivor after primary treatment | Cancer-related history and physical examination plus breast surveillance; do not use routine laboratory or imaging testing solely to detect recurrence. [12] |
| Long-term follow-up after year 5 | Annual clinical follow-up is a common guideline recommendation beginning in year 6. [2] |
| Breast imaging | Annual mammography is generally recommended beginning in year 5, individualized to surgery type and risk. [2] |
| Symptoms or examination concerning for recurrence | Use directed laboratory or imaging evaluation; do not apply an asymptomatic-surveillance restriction when clinical suspicion exists. [2] |

## Manage male breast cancer with sex-specific endocrine and surveillance considerations

Most other local and systemic management principles are extrapolated from female breast cancer care.

ASCO concludes that gene-expression testing, primary surgery, adjuvant chemotherapy, radiation therapy, and chemotherapy for advanced disease should generally follow the same approach used for women. [10] Male breast cancer nevertheless requires specific attention to endocrine therapy, germline testing, breast imaging after treatment, and treatment-related sexual and thrombotic toxicity. [10]

For hormone receptor-positive early-stage male breast cancer, offer tamoxifen for an initial duration of 5 years. Men who tolerate tamoxifen and remain at high recurrence risk after 5 years may be offered another 5 years. When tamoxifen is contraindicated, an aromatase inhibitor should be paired with a gonadotropin-releasing hormone agonist or antagonist rather than used alone. [10]

For metastatic hormone receptor-positive, HER2-negative disease, endocrine therapy is preferred first-line treatment unless there is visceral crisis or rapidly progressive disease. Options include tamoxifen, aromatase inhibitor plus gonadotropin-releasing hormone therapy, and fulvestrant; CDK4/6 inhibitors may be used as in women. [10]
- Offer germline genetic counseling and testing to all men with breast cancer. [10]
- After lumpectomy, offer ipsilateral annual mammography when technically feasible; contralateral annual mammography may be offered to men with a predisposing germline mutation. Routine breast MRI is not recommended. [10]
- Counsel about tamoxifen adverse effects and adherence: thrombotic events have been reported, with more than 80% occurring during the first 18 months in one prospective cohort. [10]

*ASCO recommendations specific to male breast cancer. [10]*

| Clinical issue | Recommendation |
| --- | --- |
| Adjuvant endocrine therapy | Offer tamoxifen for 5 years in men with HR-positive disease who are candidates for endocrine therapy. [10] |
| Tamoxifen contraindication | Consider gonadotropin-releasing hormone agonist or antagonist plus aromatase inhibitor. [10] |
| Extended therapy | Offer another 5 years of tamoxifen to selected men with high recurrence risk who tolerate initial therapy. [10] |
| Genetic assessment | Offer genetic counseling and germline genetic testing to all men with breast cancer. [10] |
| Post-lumpectomy surveillance | Offer ipsilateral annual mammography if technically feasible. [10] |

## Rebiopsy and biomarker-directed treatment remain central in metastatic disease

Management is subtype- and line-of-therapy dependent.

Contemporary metastatic breast cancer guidelines organize treatment around luminal, HER2-positive, and triple-negative disease, as well as diagnostic work-up, staging, molecular assessment, site-specific metastatic management, and survivorship. [13][17] Biomarker status drives endocrine, HER2-targeted, immunotherapy, and other targeted treatment choices. [10][17]

For men with advanced disease, ASCO supports use of targeted treatment guided by HER2, PD-L1, PIK3CA, and germline BRCA status using the same indications and combinations offered to women, while acknowledging that the male-specific evidence base is limited. [10]

Patients with inflammatory breast cancer without distant metastasis require prompt multimodality care. In a U.S. patterns-of-care cohort, only 25.8% received guideline-concordant treatment; prompt referral for neoadjuvant chemotherapy and postoperative radiation was emphasized. [20][22]
- In suspected inflammatory breast cancer, expedite multidisciplinary referral rather than treating as routine localized disease. [20][22]
- For metastatic disease, use current disease-specific guidance because treatment sequencing evolves rapidly and depends on subtype, prior exposure, molecular findings, symptoms, and organ threat. [13][17]

*Advanced breast cancer management principles available from supplied guidance. [10][13][17][20]*

| Scenario | Action |
| --- | --- |
| HR-positive, HER2-negative metastatic male breast cancer without visceral crisis | Use endocrine therapy first line; options include tamoxifen, aromatase inhibitor plus gonadotropin-releasing hormone therapy, or fulvestrant. [10] |
| Rapidly progressive disease or visceral crisis | Consider chemotherapy rather than initial endocrine therapy. [10] |
| Advanced male breast cancer with HER2, PD-L1, PIK3CA, or germline BRCA biomarkers | Use targeted treatment according to the same indications and combinations used for women. [10] |
| Nonmetastatic inflammatory breast cancer | Prompt referral for neoadjuvant chemotherapy and postoperative radiation is crucial. [20][22] |

## Common questions

### Should asymptomatic breast cancer survivors receive routine CT, PET, bone scans, or tumor-marker testing?

No. The ACS/ASCO survivorship guideline does not support routine laboratory or imaging testing solely to detect recurrence in asymptomatic survivors; use symptom- or examination-directed testing instead. [12]

### When is neoadjuvant systemic therapy most useful in breast cancer?

It is most useful when response, especially residual disease, will alter postoperative management. ASCO emphasizes high-risk HER2-positive and triple-negative disease and uses stage and receptor profile to select patients. [18]

### How long should adjuvant endocrine therapy continue?

At least 5 years is the core recommendation. Extension toward 10 years may be appropriate for selected higher-risk patients, but benefit beyond 7 to 8 years may be limited and should be balanced against toxicity and adherence. [2]

### What endocrine therapy should be used for male breast cancer?

For hormone receptor-positive early-stage disease, tamoxifen for 5 years is preferred. If tamoxifen is contraindicated, use an aromatase inhibitor with gonadotropin-releasing hormone suppression. [10]

### Should all men with breast cancer undergo germline testing?

Yes. ASCO recommends genetic counseling and germline testing for all male patients with breast cancer because inherited predisposition can affect treatment, other cancer screening, and cascade testing of relatives. [10]

## References
1. Most women diagnosed with early breast cancer can ... — www.bmj.com — https://www.bmj.com/company/newsroom/most-women-diagnosed-with-early-breast-cancer-can-expect-to-become-long-term-cancer-survivors-say-experts
2. Systematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations | British Journal of Cancer — www.nature.com — https://www.nature.com/articles/s41416-025-03059-5
3. Screening for Breast Cancer in Asymptomatic, Average ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/ANNALS-25-05116
4. Screening for Breast Cancer in Average-Risk Women — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/M18-2147
5. BREAST CANCER — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S009545430570066X#!
6. Prognostic Factor for Breast Cancer - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/prognostic-factor-for-breast-cancer
7. Prognostic and predictive parameters in breast pathology — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0893395222003672
8. incorporating the 70-gene signature into the PREDICT ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0960977625005594
9. Twenty‐year follow‐up of the breast cancers diagnosed ... — acsjournals.onlinelibrary.wiley.com — https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/canjclin.47.3.134
10. Management of Male Breast Cancer: ASCO Guideline — ascopubs.org — https://ascopubs.org/doi/10.1200/JCO.19.03120
11. Breast cancer Clinical Practice Guidelines in Oncology - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/19768876
12. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/26641959
13. ESMO Clinical Practice Guideline: Metastatic Breast Cancer — www.esmo.org — https://www.esmo.org/guidelines/esmo-clinical-practice-guideline-metastatic-breast-cancer
14. ESMO Clinical Practice Guideline: Early Breast Cancer — www.esmo.org — https://www.esmo.org/guidelines/esmo-clinical-practice-guideline-early-breast-cancer
15. International Guideline Harmonization Group ... — ascopubs.org — https://ascopubs.org/doi/10.1200/OP-25-01017
16. Review flow chart — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK550706
17. ESMO Living Guideline: ​Metastatic Breast Cancer — www.esmo.org — https://www.esmo.org/guidelines/living-guidelines/esmo-living-guideline-metastatic-breast-cancer
18. New ASCO Guideline Offers Recommendations for Neoadjuvant Breast Cancer Treatment — dailynews.ascopubs.org — https://dailynews.ascopubs.org/do/new-asco-guideline-offers-recommendations-neoadjuvant-breast-cancer-treatment
19. Review flowchart — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/n/nicecg164add/appe
20. Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer - PubMed — tools.cdc.gov — https://tools.cdc.gov/podcasts/download.asp?m=316303&c=364685
21. Selection of Optimal Adjuvant Chemotherapy and Targeted ... — ascopubs.org — https://ascopubs.org/doi/10.1200/JCO.20.02510
22. CDC Stacks — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/37858
23. ESMO Clinical Practice Guideline: Risk Reduction and Screening of Cancer in Hereditary Breast-Ovarian Cancer syndromes — www.esmo.org — https://www.esmo.org/guidelines/esmo-clinical-practice-guideline-risk-reduction-and-screening-of-cancer-in-hereditary-breast-ovarian-cancer-syndromes
24. NCDB trends in young women with metastatic breast cancer diagnosis since screening guideline changes were instituted | ACS — www.facs.org — https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/2021/01/ncdb-trends-in-young-women-with-metastatic-breast-cancer-diagnosis-since-screening-guideline-changes-were-instituted

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.